Nobel Prize Laureate Dr. Barry Marshall to Join Advisory Board of Xcelerate, Inc.

 

MAULDIN, SC -- February 23, 2021 -- InvestorsHub NewsWire -- Xcelerate, Inc (OTC: "UDHI") is honored to announce Barry James Marshall AC FRACP FRS FAA will join its Advisory Board, effective immediately. In 2005 Dr. Marshall and his longtime collaborator Dr. Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery of the bacterium Helicobacter pylori (H. pylori) and its role in peptic ulcer disease. This discovery also established the causative link between Helicobacter pylori infection and stomach cancer. Currently Dr. Marshall serves as Clinical Professor and Director of The Marshall Centre for Infectious Diseases Research at University of Western Australia. Additionally, Dr. Marshall has been involved with the establishment of the Marshall Laboratory for Biomedical Engineering at Shenzhen University

"This is truly a breakthrough day for Xcelerate," said Michael O'Shea, Xcelerate' s CEO. "Adding a Nobel Prize researcher and medical technology innovator to our Advisory Board will greatly accelerate the transition to our next phase of business development while supplying a tremendous boost toward our long-term goal of a NASDAQ listing. Xcelerate is seeking to acquire innovation at the patent/engineering level, marry it to early-stage medtech companies, and supply it in a controlled clinical care setting where developments will be trialed, tested, and applied. This will provide end-to-end controlled medtech development resulting in quicker product profitability and greater ROI by fostering engineering, clinical and business developments under one umbrella."

 

To interview either Dr. Marshall or Mr. O'Shea, contact Justin Baronoff 561-750-9800; justin@transmediagroup.com

 

This press release may contain forward-looking information within the meaning of Section 21E of Securities Exchange Act of 1934, as amended (the "Exchange Act"), including all statements not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or officers with respect to, among other things: (i) the Company's financing plans; (ii) trends affecting Company's financial condition or results of operations; (iii) Company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, beyond the Company's ability to control, and actual results may differ materially from those projected in forward-looking statements resulting from various factors.

Media Contact: Justin Baronoff 561-750-9800; justin@transmediagroup.com